Sulbactam-Durlobactam Combo Outperforms Colistin in Acinetobacter baumannii Infections
A phase 3 trial presented at IDWeek 2023 shows that sulbactam-durlobactam (SUL-DUR) reduces mortality and improves outcomes in hospital-acquired Acinetobacter baumannii-calcoaceticus complex infections compared to colistin, offering a promising treatment option.
Source: infectioncontroltoday.com